CurrentPartnering

CurrentPartnering was established in 2007 to offer an objective and informal business tool for business development executives, providing an opportunity for the dissemination of the latest trends in...

TRILOGY-ACS platelet function substudy results revealed

The platelet function substudy of the TRILOGY-ACS trial shows that there is no significant difference between prasugrel and clopidogrel in cardiovascular mortality, myocardial infarction, or stroke ou...

TRILOGY ACS: Prasugrel Fails to Beat Clopidogrel

Neutral results for prasugrel vs clopidogrel in medically managed ACS patients mean the newer antiplatelet agent cannot be recommended for use in this patient population, say the TRILOGY ACS researche...

Daiichi Sankyo and Lilly Announce TRILOGY ACS…

Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure

Prasugrel Bests Clopidogrel in TRILOGY-ACS Angiography Cohort

ACS patients randomized to prasugrel following coronary angiography had significantly lower rates of major cardiovascular events compared with patients treated with clopidogrel. The findings run count...

Daiichi Sankyo, Eli Lilly TRILOGY ACS study fails to meet primary endpoint

Daiichi Sankyo Company and Eli Lilly and Company have announced that the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) study h...

Respironics, Inc. Issues Voluntary Recall of a Limited Number of Trilogy Ventilators

MURRYSVILLE, Pa., July 17, 2012 /PRNewswire/ -- Respironics, Inc. announced today that it is voluntarily recalling 80 Trilogy Model 100 and five Trilogy Model 202 ventilators in the United States...

Results of the TRILOGY ACS Angiographic Cohort presented at TCT 2012

(Cardiovascular Research Foundation) A study has found that the anti-clotting medication prasugrel reduced cardiovascular events among patients who present with an acute coronary syndrome and are mana...

Prasugrel Versus Clopidogrel For ACS Patients Managed Without Revascularisation: The TRILOGY ACS Study

The first trial to study the effect of platelet inhibition in patients with acute coronary syndromes managed medically without revascularisation has found no significant difference between prasugrel a...

A review of telemedicine business models.

Abstract Telemedicine has become an increasingly popular option for long-distance/virtual medical care and education, but many telemedicine ventures fail to grow beyond the initial pilot stage. Studyi...

CEE-ing is believing: Bioscience ventures in Central and Eastern Europe.

Bioscience ventures in Central and Eastern Europe are becoming a presence in world healthcare markets despite a perennially short supply of venture funding and other support mechanisms relative to oth...

Large-head metal-on-metal total hip arthroplasty using the Durom acetabular component at minimum 1-year interval.

Large-head metal-on-metal total hip arthroplasty represents novel technology, and outcome data are lacking. We prospectively compared the performance of a nonmodular metal-on-metal acetabular componen...

Sutureless aortic valve replacement with the Trilogy Aortic Valve System: Multicenter experience.

OBJECTIVE: To evaluate the modular sutureless Arbor Trilogy Aortic Valve System (Arbor Surgical Technologies, Irvine, Calif), designed for minimally invasive aortic valve replacement. METHODS: In a pr...

Vision in Venture: Angels of innovation.

Convincing someone to risk money is often the first tangible evidence that a new technology has real market potential. While there's no shortage of impressive new technologies or startups in Israel to...